CDMO manufacturing pharmaceutical intermediates, APIs and specialty chemicals for global pharma and life-sciences companies.
CDMO manufacturing pharmaceutical intermediates, APIs and specialty chemicals for global pharma and life-sciences companies.
In one line: A newer Indian pharma/specialty-chemical CDMO.
Moat: narrow (process know-how, regulatory licence). Regulated manufacturing plants and multi-year CDMO contracts create switching costs for pharma clients.
Headquarters: Hyderabad, India · Employees: 5,051
Size Cohance Lifesciences (COHANCE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.87B, the 396th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹456.40 on 18 Nov 2026.
Performance Over six months the shares gained 6.5%, against -12.4% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 13.7% over the last twelve months (peer median +9.4%); the operating margin is 1.6% (peer median 15.0%).
Valuation It trades at 96.3× forward earnings against a peer median of 15.7× (2nd most expensive of 20).
Capital Return on invested capital runs 14.9 points below its cost of capital (15.5% WACC).
Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹20.6B | ₹22.4B | ₹25.7B | ₹10.4B | ₹13.3B |
| Revenue growth | — | -13% | +148% | -22% | — |
| Gross profit | ₹6.98B | ₹4.85B | ₹8.64B | ₹4.38B | ₹5.87B |
| EBITDA | ₹2.31B | ₹4.15B | ₹8.06B | ₹4.05B | ₹5.84B |
| Net income | ₹474M | ₹1.79B | ₹4.87B | ₹3.00B | ₹4.11B |
| Free cash flow | n/a | ₹1.35B | ₹3.31B | ₹3.29B | ₹1.66B |
| Capital expenditure | n/a | ₹2.20B | ₹3.17B | ₹519M | ₹2.86B |
| Total debt | ₹4.48B | ₹4.00B | ₹4.86B | ₹650M | ₹703M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cohance Lifesciences COHANCE.NS | $1.87B | +7% | +14% | 2% | 96.3× | n/a |
| Neuland Laboratories NEULANDLAB.NS | $2.95B | +28% | +50% | 26% | 63.4× | n/a |
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
| Piramal Pharma PPLPHARMA.NS | $3.40B | +38% | +9% | 3% | 150.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COHANCE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.3% | +0.7% | 10th lowest of 21 |
| 6-month return | +6.5% | -12.4% | 3rd highest of 21 |
| Distance from 52-week high | -32.5% | -27.6% | 9th lowest of 21 |
| Revenue growth (TTM) | +13.7% | +9.4% | 7th highest of 21 |
| Operating margin | 1.6% | 15.0% | 3rd lowest of 21 |
| Forward P/E | 96.3× | 15.7× | 2nd most expensive of 20 |
| ROIC minus cost of capital | -14.9 pp | +0.7 pp | 3rd lowest of 21 |
| EV / EBITDA | 76.7× | 11.6× | most expensive of 11 |
| Net debt / EBITDA | 0.7× | 1.1× | 5th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |